Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Items 501–600 of 914
Dimri, M., Cho, J., Kang, M., & Dimri, G. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.615179 · Cited by 27
He, Y., Jin, Y., Zhang, Y., Meng, H., Zhao, B., Jiang, Y., Zhu, J.-W., Liang, G.-Y., Kong, D., & Jin, X. (2014) · Translational research · doi:10.1016/j.trsl.2014.09.005 · Cited by 27
Wei, J., Yin, L., Li, J., Wang, J., Pu, T., Duan, P., Lin, T., Gao, A. C., & Wu, B. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0198 · Cited by 27
Bmi-1 induces radioresistance by suppressing senescence in human U87 glioma cells
Ye, L., WANG, C., Yu, G., Jiang, Y., Sun, D., Zhang, Z., Yu, X., Li, X., WEI, W., Liu, P., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2606 · Cited by 27
“Bmi-1 has also been reported to be overexpressed in certain gliomas that usually possess a poor prognosis (16-18).”
Davis, P. J., Glinsky, G. V., Lin, H., Incerpi, S., Davis, F. B., Mousa, S. A., Tang, H. Y., Hercbergs, A. A., & Luidens, M. K. (2013) · Endocrine Research · doi:10.3109/07435800.2013.778865 · Cited by 27
Self-citationAbnormal Kinetochore-Generated Pulling Forces from Expressing a N-Terminally Modified Hec1
Mattiuzzo, M., Vargiu, G., Totta, P., Fiore, M., Ciferri, C., Musacchio, A., & Degrassi, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016307 · Cited by 35
“Moreover, Hec1 overexpression has been associated to poor clinical prognosis in non small cell lung cancers, breast cancers and patients with multiple cancers [33,34].”
BackgroundChen, X., Li, D., Gao, Y., Tang, W., Lao, I. W., Cao, Y., & Hao, B. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488836 · Cited by 26
Raso, M. G., & Wistuba, I. I. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318074fe42 · Cited by 27
Peixoto, B. R., Vêncio, R. Z. N., Egidio, C., Mota‐Vieira, L., Verjovski‐Almeida, S., & Reis, E. M. R. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-35 · Cited by 27
Yanagisawa, K., Konishi, H., Arima, C., Tomida, S., Takeuchi, T., Shimada, Y., Yatabe, Y., Mitsudomi, T., Osada, H., & Takahashi, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1055 · Cited by 25
Cytoplasmic ATXN7L3B Interferes with Nuclear Functions of the SAGA Deubiquitinase Module
Li, W., Atanassov, B. S., Lan, X., Mohan, R. D., Swanson, S. K., Farria, A. T., Florens, L. A., Washburn, M. P., Workman, J. L., & Dent, S. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00193-16 · Cited by 26
“As early as 2005, USP22 was identified as a member of an 11-gene “deathfrom-cancer” signature for highly aggressive tumors (15).”
BackgroundUSP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma
Zeng, K., Xie, W., Wang, C., Wang, S., Liu, W., Su, Y., Lin, L., Zou, R., Sun, G., Zhou, B., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05699-y · Cited by 30
“Having demonstrated that USP22 is identified as one of the 11 genes to be involved in cancer-related death signatures, and plays a crucial role in the progression of tumor [6, 52].”
BackgroundDirix, L. Y., van Dam, P. A., & Vermeulen, P. B. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000183669.61767.81 · Cited by 29
Yip, Y., Tsang, C., Deng, W., Cheung, P.-Y. P., Jin, Y., Cheung, A. L. M., Lung, M. L., & Tsao, S. (2010) · Journal of Medical Virology · doi:10.1002/jmv.21875 · Cited by 29
“In addition, Bmi-1 is involved in stem cell renewal and may drive multiple pathways related to expression of stem-cell phenotype [Glinsky et al., 2005].”
BackgroundFlickin’ the ubiquitin switch: The role of H2B ubiquitylation in development
Wright, D. E., Wang, C., & Kao, C.-F. (2011) · Epigenetics · doi:10.4161/epi.6.10.17745 · Cited by 30
Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma
Zhou, J., Zhong, H., Zhang, J., Jin, S., Roudi, R., & Ma, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00078 · Cited by 25
Qi, Y., Su, B., Liu, D., Liu, B., Fan, Y., Wang, Y., & Meng, X. (2007) · Oligonucleotides · doi:10.1089/oli.2007.0070 · Cited by 25
“…such as leukemia (Sawa et al., 2005), mantle cell lymphoma (Bea et al., 2001), non-small–cell lung cancer (Vonlanthen et al., 2001), breast cancer (Kim et al., 2004a), colorectal cancer (Kim et al., 2004b), nasopharyngeal carcinoma (Song et al., 2006), and prostate cancer (Glinsky et al., 2005).”
Zhang, X., Sun, J., Wang, H., Lou, Y., Zhang, Y., Sha, H., Feng, J., & Han, B. (2013) · Tumor Biology · doi:10.1007/s13277-013-1100-9 · Cited by 24
Menyhárt, O., Kakisaka, T., Pongor, L. S., Uetake, H., Goel, A., & Győrffy, B. (2019) · Cancers · doi:10.3390/cancers11070983 · Cited by 24
“ANK3 (Ankyrin G) provides cellular stability by anchoring cytoskeleton to the plasma membrane, and its down-regulation has been associated with poor prognosis [35] and increased invasive potential [36] in solid malignancies.”
BackgroundInhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel
Mo, Q., Chen, P., Jin, X., Chen, Q., Tang, L. Y., Wang, B., Li, K., Wu, P., Fang, Y., Wang, S., et al. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.197 · Cited by 24
Giordano, A., Fucito, A., Romano, G., & Marino, I. R. (2007) · Frontiers in bioscience · doi:10.2741/2328 · Cited by 25
“lymphoma, mantle cell lymphoma, acute myeloid leukemia, mesothelioma, medulloblastoma and malignant glioma (63).”
BackgroundInfluentialPerumal, D., Singh, S., Yoder, S., Bloom, G. C., & Chellappan, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043589 · Cited by 24
“However the use of microarrays in clinical practice is limited by the large number of genes used in gene profiling and lack of both reproducibility and independent validation [11,12,13].”
BackgroundSelection of Brain Metastasis-Initiating Breast Cancer Cells Determined by Growth on Hard Agar
Guo, L., Fan, D., Zhang, F., Price, J. E., Lee, J., Marchetti, D., Fidler, I. J., & Langley, R. R. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.047 · Cited by 30
“Metastatic tumor cells in both mice and humans have also been shown to express genes that are characteristic of stem cells.(32) The present results suggest that both the in vitro and in vivo selection processes enrich for subpopulations of breast cancer cells that express CD44 and CD133, two of the markers that have b…”
BackgroundA reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer
Warren, A. Y., Massie, C. E., Watt, K., Luko, K., Orafidiya, F. A., Selth, L. A., Mohammed, H., Chohan, B. S., Menon, S., Baridi, A., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0501-z · Cited by 27
“High levels of PBK transcript levels are associated with poor recurrence-free survival in the b Taylor cohort [21] and c in Glinsky data set [23].”
BackgroundMetzger, G. J., Dankbar, S. C., Henriksen, J. C., Rizzardi, A. E., Rosener, N. K., & Schmechel, S. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033520 · Cited by 23
“In prostate cancer, numerous publications have identified n-gene molecular signatures that are correlated with biochemical failure versus non-failure following prostatectomy [49,50,51,52,53,54].”
BackgroundFuture developments in the management of malignant pleural mesothelioma
Zucali, P. A., Vincenzo, F. D., Simonelli, M., & Santoro, A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.2 · Cited by 23
The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth
Setoguchi (2010) · Oncology Reports · doi:10.3892/or_00000684 · Cited by 24
Reiner, T., Pozas, A. D. L., Parrondo, R. D., & Perez‐Stable, C. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0024 · Cited by 23
“Support for the hypothesis that more aggressive and metastatic cancers express stem cell– like genes comes from the identification of the 11-gene signature as a powerful predictor of unfavorable patient prognosis in 11 distinct types of cancer, including prostate cancer (18).”
BackgroundTumor-Associated Antigens and Biomarkers in Cancer and Immune Therapy
Malyankar, U. M. (2007) · International Reviews of Immunology · doi:10.1080/08830180701402496 · Cited by 23
Cancer Development and Progression
He, M., Rosen, J. E., Mangiameli, D. P., & Libutti, S. K. (2007) · Springer eBooks · doi:10.1007/978-0-387-39978-2_12 · Cited by 22
Kanno, R., Janakiraman, H., & Kanno, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00797.x · Cited by 25
RetractedSystems biology and cancer stem cells
Price, N. D., Foltz, G., Madan, A., Hood, L., & Tian, Q. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00151.x · Cited by 27
“For example, an 11gene signature for “stem-ness” in multiple cancer types has been identified [46] that predicts short interval to disease recurrence, distant metastasis and death from cancer.”
BackgroundChen, Y., Lian, G., Ou, G., Yang, K., Chen, J., Li, H., Chen, S., Li, J., Zeng, L., & Huang, K. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0485-0 · Cited by 23
“Aberrant Bmi-1 expression has been reported in a variety of human cancers [8–13].”
BackgroundYang, X., Zang, H., Luo, Y., Wu, J., Fang, Z., Zhu, W., & Li, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s148662 · Cited by 23
“8,9 Cancer stem cells characterized by the 11-gene signature are associated with metastasis, enabling anoikis resistance and aberrant cell cycle control.”
Ling, S., Sun, D., Tang, B., Guo, C., Zhang, Y., Liang, R., & Wang, L. (2012) · PubMed · Cited by 24
Zheng, X., Wang, Y.-F., Liu, B., Liu, C., Liu, D., Zhu, J., Yang, C., Yan, J., Liao, X., Meng, X., et al. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0459 · Cited by 22
“Bmi-1 expression is upregulated in a variety of human cancers, including NSCLC ( Kim et al., 2004; Glinsky et al., 2005; Sawa et al., 2005; Song et al., 2006; Becker et al., 2009), therefore, Bmi-1 might play an important role in tumorigenesis.”
BackgroundCoscio, A. M., Chang, D. W., Roth, J. A., Ye, Y., Gu, J. H., Yang, P., & Wu, X. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu034 · Cited by 24
“In lung cancer as well as several other solid tumor types, this signature has been associated with death from cancer as opposed to long-term remission after treatment for early-stage disease (16).”
BackgroundThe challenge of gene expression profiling in heterogeneous clinical samples
Rodríguez-González, F. G., Mustafa, D. A. M., Mostert, B., & Sieuwerts, A. M. (2012) · Methods · doi:10.1016/j.ymeth.2012.05.005 · Cited by 28
Ferrara, M., Sessa, G., Fiore, M., Bernard, F., Asteriti, I. A., Cundari, E., Colotti, G., Ferla, S., Desideri, M., Buglioni, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.320 · Cited by 24
USP22 Suppresses SPARC Expression in Acute Colitis and Inflammation-Associated Colorectal Cancer
Kosinsky, R. L., Saul, D., Ammer‐Herrmenau, C., Faubion, W. A., Neeße, A., & Johnsen, S. A. (2021) · Cancers · doi:10.3390/cancers13081817 · Cited by 22
“Ubiquitin-specific protease 22 (USP22) was identified as a member of the so-called 11-gene “death-from-cancer” expression signature which was associated with distant metastasis, high recurrence rates and poor patient survival in several cancer entities, including CRC [5,6].”
BackgroundBennett, C. N., & Green, J. E. (2008) · Breast Cancer Research · doi:10.1186/bcr2125 · Cited by 23
“Interestingly, based upon the hypothesis that cancer stem cells are enriched in metastatic tumors [62], Glinsky and colleagues [63] identified a metastasis signature, through comparison of primary and metastatic prostate tumors isolated from transgenic mice that express SV40 T/t antigen, and a stem cell signature, thr…”
BackgroundEpithelial Stem Cells of the Prostate and Their Role in Cancer Progression
Lukacs, R. U., Lawson, D. A., Xin, L., Zong, Y., Garraway, I. P., Goldstein, A. S., Memarzadeh, S., & Witte, O. N. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.012 · Cited by 25
The expression of stem cell‐related indicators as a prognostic factor in human lung adenocarcinoma
Zhang, X., Dong, Q., Huang, J., Huang, A., Shi, C., Jin, B., Sha, H., Feng, J., Qin, G., Zhou, J., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21718 · Cited by 21
“Similar to stem cells, recent data have suggested the presence of a conserved Bmi-1-driven pathway that is also involved in the development of a highly malignant subset of human cancers [27].”
BackgroundRole of H2B mono-ubiquitination in the initiation and progression of cancer
Zhou, S., Cai, Y., Liu, X., Jin, L., Wang, X., Ma, W., & Zhang, T. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.12.007 · Cited by 23
Stefansson, I. M., Raeder, M. B., Wik, E., Mannelqvist, M., Kusonmano, K., Knutsvik, G., Haldorsen, I. S., Trovik, J., Oyan, A. M., Kalland, K.-H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3521 · Cited by 22
“We next examined the correlation between our 32gene score and 6 different gene signatures previously reported to reflect angiogenesis and outcome in a range of cancers: a VEGF signature [25], a vascular invasion signature [26], a wound response signature [27], a hypoxia gene signature [28], a TGFβ gene-response signat…”
BackgroundMethodYoshikawa, R., Tsujimura, T., Tao, L., Kamikonya, N., & Fujiwara, Y. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-461 · Cited by 21
“Recent studies have documented increased BMI1 expression in a variety of human cancers, such as non-small cell lung cancers [21], medulloblastomas [22], prostate carcinomas [23], colorectal cancers [24], breast carcinomas [25], and oesophageal squamous cell carcinomas (ESCCs) [26].”
BackgroundSus1/ENY2: a multitasking protein in eukaryotic gene expression
Galán, A., & Rodríguez‐Navarro, S. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.730498 · Cited by 23
“Actually, the deubiquitination activity of the hSAGA complex has been more directly implicated in cancer as USP22 has been grouped by transcriptional Critical Reviews in Biochemistry and Molecular Biology profiling into an 11-gene signature, which also includes polycomb repressor PRC1 and self-renewal marker BMI1 (Gli…”
BackgroundChuang, S., Lee, Y.-S. E., Huang, L. Y. L., Chen, C., Lai, C., Lin, Y., Yang, J., Yang, S., Chang, L.-H., Chen, C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112118 · Cited by 21
Kumar, S. S., Sengupta, S., Zhu, X., Mishra, D. K., Phoenix, T. N., Dyer, L. M., Fuller, C. E., Stevenson, C. B., DeWire, M. D., Fouladi, M., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0099 · Cited by 21
“Glinsky signature and stemness score Glinsky score was calculated as previously described (12).”
BackgroundMethodSasaki, M., Yamaguchi, J., Ikeda, H., Itatsu, K., & Nakanuma, Y. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.01.027 · Cited by 21
Overexpression of BMI1, a polycomb group repressor protein, in bladder tumors: a preliminary report.
Shafaroudi, A. M., Mowla, S. J., Ziaee, S. A. M., Bahrami, A. R., Atlasi, Y., & Malakootian, M. (2008) · Urology journal./Urology jornal. · Cited by 24
Integrative analysis of survival-associated gene sets in breast cancer
Varn, F. S., Ung, M. H., Lou, S., & Cheng, C. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0086-0 · Cited by 23
“There now exist several multi-gene signatures that have been developed to improve upon the predictions of single-gene markers [2-16].”
BackgroundNucleic acid-based marker approaches to urologic cancers
Veltri, R. W., & Makarov, D. V. (2006) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2006.07.002 · Cited by 21
A taxonomy of epithelial human cancer and their metastases
Gevaert, O., Daemen, A., Moor, B. D., & Libbrecht, L. J. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-69 · Cited by 23
“developed an 11-gene signature that was predictive of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with many types of cancer [14].”
Two-transcript gene expression classifiers in the diagnosis and prognosis of human diseases
Edelman, L. B., Toia, G. V., Geman, D., Zhang, W., & Price, N. D. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-583 · Cited by 23
Epigenetic Signatures In Stem Cells And Cancer Stem Cells
Hernández‐Vargas, H., Sinčić, N., Ouzounova, M., & Herceg, Z. (2009) · Epigenomics · doi:10.2217/epi.09.19 · Cited by 25
Biomarkers for the Development of Cancer Vaccines
Copier, J. P., Whelan, M., & Dalgleish, A. G. (2006) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256210 · Cited by 20
Tolani, B., Acevedo, L. A., Hoang, N. T., & He, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010238 · Cited by 23
“The activation of stem cell signaling is generally regulated and chronic stimulation and accompanying oncogenic events in these developmental pathways are correlated with poor prognosis in MPM patients [84].”
BackgroundHe, W., Chen, L., Yuan, K., Zhou, Q., Peng, L., & Han, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.55 · Cited by 20
Alterations of Histone Modifications in Cancer
Hosseini, A., & Minucci, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812215-0.00006-6 · Cited by 33
Expression of the Polycomb-Group Protein BMI1 and correlation with p16 in astrocytomas
Tirabosco, R., Maglio, G. D., Škrap, M., Falconieri, G., & Pizzolitto, S. (2008) · Pathology - Research and Practice · doi:10.1016/j.prp.2008.02.007 · Cited by 20
Wu, G., Wei, R. L.-H., Cheng, E., Ngo, B., & Lee, W. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-11-1123 · Cited by 21
“Importantly, Hec1 overexpression has been observed in a variety of human cancers and was found to associate with adverse clinical outcomes of primary breast cancers and cases with multiple cancers (Chen et al., 1997a; van’t Veer et al., 2002; Glinsky et al., 2005).”
BackgroundEffect of siRNA‐mediated silencing of Bmi‐1 gene expression on HeLa cells
Jiang, Y., Su, B., Meng, X., Liu, C., Liu, B., Liu, D., Fan, Y., & Yang, H. Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01417.x · Cited by 20
METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy
Zhuang, X., Yin, S., Ji, C., Sun, W., Fang, Z., Xiang, Y., Peng, E.-Y., Yao, Y., Li, Y., He, X., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107509 · Cited by 21
Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway
Srivastava, S., Mohibi, S., Mirza, S., Band, H., & Band, V. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1339846 · Cited by 19
“It is intriguing that the STAGA complex, of which ADA3 is a component within the HAT module, harbors a deubiquitinase USP22; importantly, USP22 is part of an 11 gene signature that correlates with poor prognosis in multiple cancers.(35) Whether USP22 is the deubiquitinase for ADA3 that may contribute to its acetylatio…”
Backgroundbub1 as a potential oncogene and a prognostic biomarker for neuroblastoma
Song, J., Ni, C., Dong, X., Sheng, C., Qu, Y., & Zhu, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.988415 · Cited by 22
Dimov, I., Višnjić, M., & Stefanović, V. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.138 · Cited by 20
“A genomics approach revealed an 11-gene signature (including BMI1) that consistently displayed a stem-cell-resembling expression profile in distant metastatic lesions of different cancers, including bladder cancers[107].”
BackgroundLawson, A. P., Bak, D. W., Shannon, D. A., Long, M. J. C., Vijaykumar, T., Yu, R., Oualid, F. E., Weerapana, E., & Hedstrom, L. (2017) · Oncotarget · doi:10.18632/oncotarget.17261 · Cited by 20
“USP22 Chromatin remodeling [79] Cell proliferation [77, 79, 112] Protein stability Gene expression [78, 113] Telomere maintenance [114] H2A [115] H2B [116] TRF1 [114] COX-2 [80] FBP1 [81] ↓ (this work) ↓ (this work) ? ↓ [84] ↑ p21 [82, 83, 117]2”
Tu, S. (2010) · Cancer treatment and research · doi:10.1007/978-1-4419-5968-3_10 · Cited by 19
In Arrayed Ranks: Array Technology in the Study of Mesothelioma
Gray, S. G., Fennell, D. A., Mutti, L., & O'Byrne, K. J. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181951ce8 · Cited by 21
Zhuang, Y.-J., Liao, Z.-W., Yu, H., Song, X., Liu, Y., Shi, X., Lin, X., & Zhou, T. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.987029 · Cited by 19
Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer
Buechel, M. E., Dey, A., Dwivedi, S. K. D., Crim, A. K., Ding, K., Zhang, R., Mukherjee, P., Moore, K. N., Cao, L., Branstrom, A. A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1192 · Cited by 19
Lü, Y., Liu, P., den Bergh, F. V., Zellmer, V. R., James, M. A., Wen, W., Grubbs, C. J., Lubet, R. A., & You, M. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0363 · Cited by 20
“Altered expression of Bub1 is associated with therapy failure and death in patients with multiple types of cancer (35).”
BackgroundEpigenetic Regulation and Dietary Control of Triple Negative Breast Cancer
Selmin, O. I., Donovan, M. G., Stillwater, B. J., Neumayer, L. A., & Romagnolo, D. F. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00159 · Cited by 21
“B lymphoma Mo-MLV insertion region 1 homolog (BMI1) is a protein of the polycomb group involved in epigenetic regulation and overexpressed in many cancer types including breast (19).”
BackgroundFunction and regulation of the Spt-Ada-Gcn5-Acetyltransferase (SAGA) deubiquitinase module
Cornelio-Parra, D. V., Goswami, R., Costanzo, K. M., Morales‐Sosa, P., & Mohan, R. D. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194630 · Cited by 20
Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma
Zakrzewska, M., Zakrzewski, K. M., Grešner, S. M., Piaskowski, S., Zalewska‐Szewczyk, B., & Liberski, P. P. (2010) · Child s Nervous System · doi:10.1007/s00381-010-1260-5 · Cited by 18
“suggested the usefulness of BMI1 expression in prediction of outcomes in medulloblastoma [13].”
BackgroundKim, K., Ro, J. Y., Kim, S. G., & Cho, Y. M. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.006 · Cited by 18
“It has recently been shown that CSCs are highly resistant to conventional chemo-/ radiation therapy and that the molecular imprints of stemness might serve as molecular predictors of the cancer therapy outcome [6].”
BackgroundA gene sets approach for identifying prognostic gene signatures for outcome prediction
Kim, S., & Kim, S. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-177 · Cited by 18
“[55] 15931389_ST2_14 14 14 Glinsky et al.”
Rosado, J. O., Henriques, J. A. P., & Bonatto, D. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798977 · Cited by 22
“Overexpression of NDC80/HEC1 has been associated with poor clinical outcomes in primary breast cancers and in cases with multiple cancers [114, 115].”
BackgroundTargeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Giuffrida, D., & Rogers, I. M. (2010) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489210791760535 · Cited by 18
A signature for induced pluripotent stem cell–associated genes in colorectal cancer
Liu, Y., Li, Y., Liu, X.-H., Sui, H., Liu, Y.-X., Xiao, Z., Zheng, P., Chen, L., Yao, S., Xing, C., et al. (2013) · Medical Oncology · doi:10.1007/s12032-012-0426-2 · Cited by 18
Cloud, V. J., Thapa, A., Morales‐Sosa, P., Miller, T. M., Miller, S., Holsapple, D., Gerhart, P. M., Momtahan, E., Jack, J. L., Leiva, E., et al. (2019) · eLife · doi:10.7554/elife.49677 · Cited by 17
Physical Exercise-Associated Gene Expression Signatures in Peripheral Blood
Kawai, T., Morita, K., Masuda, K., Nishida, K., Sekiyama, A., Teshima-Kondo, S., Nakaya, Y., Ohta, M., Saito, T., & Rokutan, K. (2007) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0b013e31814c3e4f · Cited by 21
Fu, W.-M., Tang, L., Zhu, X. M., Lu, Y., Zhang, Y., Lee, W., Wang, H., Yu, Y., Liang, W., Ko, C., et al. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1047-3 · Cited by 17
Breast Cancer Stem Cells: The Other Side of the Story
Wicha, M. S. (2007) · Stem Cell Reviews and Reports · doi:10.1007/s12015-007-0016-4 · Cited by 17
“This is consistent with recent publications indicating a correlation of “stem cell self-renewal” gene expression signatures with poor clinical outcome in breast cancer and other malignancies [6].”
ResultCDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia
Mariani, S. A., Minieri, V., Dominici, M. D., Iacobucci, I., Peterson, L. F., & Calabretta, B. (2016) · Leukemia · doi:10.1038/leu.2016.70 · Cited by 18
Bustin, S. A. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.3.201 · Cited by 18
Li, C., Wang, Z., Chen, W., Cao, B., Zhang, M., Gu, Q., Qi, S., Fei, X., Shi, Y., Li, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.697247 · Cited by 17
“As shown in Figure 6A and Table 2, the following 20 drug targets regulated the 8 potential metabolites directly: BCHE, ALOX5, PTGS2, PTGS1, LPL, CES1, PLA2G2E, PLA2G1B, UGCG, PPARG, LCT, ADRA1A, ADRB1, ADRB2, MAOB, ADRA2A, MAOA, Frontiers in Oncology | www.frontiersin.org 7 TAAR1, ADRA2B, and GATM.”
BackgroundInfluentialMannelqvist, M., Wik, E., Stefansson, I. M., & Akslen, L. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098787 · Cited by 17
“The BMI-1 driven gene signature shows prognostic impact in many cancers [22].”
BackgroundIs cancer a stem cell disease? Theory, evidence and implications
Blacking, T., Wilson-Robles, H. M., & Argyle, D. J. (2007) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00127.x · Cited by 16
Vecchio, F. D., Gallo, F., Marco, A. D., Mastroiaco, V., Caianiello, P., Zazzeroni, F., Alesse, E., & Tessitore, A. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0836-1 · Cited by 16
Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer
Kurozumi, S., Joseph, C., Raafat, S., Sonbul, S. N., Kariri, Y. A., Alsaeed, S. A., Pigera, M., Alsaleem, M. A., Nolan, C. C., Johnston, S. J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05216-w · Cited by 20
Althobiti, M. M., Muftah, A. A., Aleskandarany, M. A., Joseph, C., Toss, M. S., Green, A. R., & Rakha, E. A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05719-x · Cited by 18
Live or let die: oestrogen regulation of survival signalling in endocrine response
Butt, A. J., Sutherland, R. L., & Musgrove, E. A. (2007) · Breast Cancer Research · doi:10.1186/bcr1779 · Cited by 16
“Although predominated by gene sets involved in proliferation and mitogenic signalling, several recent studies in breast cancer cohorts have identified prognostic signatures that involve cell death and cell survival signalling [17, 18 ], and a limited number of studies have more specifically identified signatures that…”
The top cited articles on glioma stem cells in Web of Science.
Yi, F., Ma, J., Ni, W., Chang, R., Liu, W., Han, X., Pan, D., Liu, X., & Jian-wu, Q. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.15.011 · Cited by 18
“As to the subject categories, of the top 63 cited articles, 22 articles were related to cell biology [14-35] , 20 to oncology [36-51] , eight to neurology [52-59] , five to biochemistry and molecular biology [60-64] , and the rest to other areas of biology [65-76] .”
BackgroundOverexpression of Bmi-1 Induces the Malignant Transformation of Gastric Epithelial Cells In Vitro
Chen, Y., Lian, G., Qiubo, Z., Zeng, L., Qian, C., Chen, S., & Huang, K. (2013) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13786659070316 · Cited by 16
More than meets the eye: the changing face of histopathology
Underwood, J. C. E. (2016) · Histopathology · doi:10.1111/his.13047 · Cited by 20
“the fusion gene product resulting from t(X:18) in synovial sarcoma), a tumour’s gene expression profile may predict, more powerfully than can histological criteria, a favourable prognosis(22) or, conversely, therapy failure.(23) Purely descriptive diagnoses based solely on morphology, such as small blue round-cell tum…”
BackgroundShoushtari, A. N., Michalowska, A. M., & Green, J. E. (2007) · Breast Disease · doi:10.3233/bd-2007-28105 · Cited by 18
“Glinsky et al compared primary and metastatic tumors in the probasin-T/t Antigen (TRAMP) model of prostate carcinoma and found elevated levels of Bmi-1 [74], a a member of the polycomb transcriptional repressors implicated in stem cell re-newal [75–78], in the metastases.”
Molecular targets in gynaecological cancers
Cheung, A. (2007) · Pathology · doi:10.1080/00313020601153273 · Cited by 18
Lu, W., Chu, P., Tang, A., Si, L., & Fang, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116974 · Cited by 19
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.